Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study

Barbara RomanowskiUniversity of Alberta; Edmonton, AB, CanadaCorrespondence[email protected]

Tino F SchwarzCentral Laboratory and Vaccination Center; Stiftung Juliusspital; Würzburg, Germany

Linda FergusonColchester Research Group; Truro, NS, Canada

Klaus PetersBerner Heerweg 157; Hamburg, Germany

Marc DionneCentre Hospitalier Universitaire; Québec, QC, Canada

Ulrich BehreHauptstrasse 240; Kehl Baden-Württemberg; Germany

Karin SchulzeWaisenhausstrasse 52; Munich, Germany

Peter HillemannsMedizinische Hochschule Hannover; Hannover, Germany

Pemmaraju SuryakiranGlaxoSmithKline; Bangalore, India

Florence ThomasGSK Vaccines; Wavre, Belgium

Frank StruyfGSK Vaccines; Wavre, Belgium

Your download is now in progress and you may close this window